Company news
Polynovo Limited (ASX:PNV) news
Polynovo Limited news releases on 6ix. Latest, Oct 6, 2022: Q1 FY23 Sales Result
Press releases — page 2
Q1 FY23 Sales Result
October 5, 2022
FDA 510(k) clearance for NovoSorb MTX
September 18, 2022
Trading halt
September 16, 2022
Pause in trading
September 16, 2022
PolyNovo FY22 Briefing Session
August 26, 2022
FY22 Results Presentation
August 26, 2022
Appendix 4E and FY22 Financial Statements
August 26, 2022
First Patient enrolled - SynPath Diabetic Foot Ulcer Trial
August 10, 2022
CEO Appointment - Swami Raote
July 29, 2022
S&P DJI Announces June 2022 Quarterly Rebalance
June 3, 2022
Trading Update Q3 FY22
April 6, 2022
Appendix 4D and 1H FY22 Report
February 24, 2022
1H FY22 Results Presentation
February 24, 2022
1H22 Indicative Trading Result (unaudited)
January 10, 2022
Record US sales in July and Nov, and other matters
December 13, 2021
Managing Director resignation
November 5, 2021
Q1 FY22 Trading Update - Clarification Announcement
October 29, 2021
Chairman and Managing Director - AGM address
October 26, 2021
COVID Trading Themes - Q1 FY22 Update
October 20, 2021
First patient enrolled in Pivotal Trial - BARDA
September 21, 2021
FY21 Results Presentation
August 26, 2021
Appendix 4E and FY21 Financial Statements
August 26, 2021
FY21 BTM Revenue Results
July 12, 2021
PolyNovo signs with Premier Inc. (GPO)
March 25, 2021
Distributor App. - PolyNovo enters Denmark, Norway & Iceland
February 24, 2021
H1 FY21 Results Investor Presentation
February 22, 2021
Appendix 4D and H1 FY21 Report
February 22, 2021
PolyNovo enters Italy - Distributor Appointment
February 1, 2021
PolyNovo enters Turkey - Distributor Appointment
January 19, 2021
PolyNovo enters Poland - Distributor Appointment
January 19, 2021
Response to ASX Query
January 17, 2021
Trading Update - H1 FY21
January 11, 2021
PolyNovo enters Belgium, Netherlands, Luxemburg & Sweden
November 18, 2020
Chairman, Managing Director & SVP of Sales US - AGM address
November 13, 2020
USA FDA approves Pivotal Trial IDE
November 12, 2020
Taiwan FDA Approval for PolyNovo
October 27, 2020
Appointment of distributor for Finland
September 22, 2020
FY20 Results Presentation
August 26, 2020
Appendix 4E and FY20 Annual Report
August 26, 2020
BARDA funding for Pivotal Trial
July 14, 2020
Trading Update
July 9, 2020
Pivotal Trial Protocol - Update
July 9, 2020
Appt Brennan as MD PNV
April 23, 2020
Feasibility Study Results Summary
April 21, 2020
Debt Finance Facility
April 6, 2020
Letter to Shareholders
March 10, 2020
Half Year Results 2020 Presentation
February 25, 2020
CEO interviewed by Alan Kohler
February 4, 2020
UK/Ireland Progress Update
January 28, 2020
Europe Progress Update
January 21, 2020